Henry Schein (HSIC) stock is in focus after first quarter results highlighted steady U.S. dental and technology performance, reaffirmed full year guidance, and an industry report that places clinical execution, not scale, at the center of practice growth.

Henry Schein’s recent Q1 update, reaffirmed 2026 outlook and ongoing buybacks have supported sentiment. However, the stock’s 30 day share price return is down 6.07% and its 1 year total shareholder return is only 0.93%, suggesting momentum has cooled after earlier gains.

If you are weighing Henry Schein’s steady, service driven model against other opportunities in healthcare technology, it may be worth scanning 32 healthcare AI stocks

With Henry Schein trading at US$72.72 and sitting at a sizeable discount to one estimate of intrinsic value and to the average analyst target, the question is whether this is genuine mispricing or if the market already sees future growth playing out.

Most Popular Narrative: 19.4% Undervalued

Henry Schein’s most followed narrative pegs fair value at about $90.21 per share, compared with the recent $72.72 price, putting the focus firmly on execution in its higher margin segments.

The company is experiencing strong growth in high-margin businesses such as Specialty Products, Technology, and private-label offerings, and expects over 50% of non-GAAP operating income to come from these segments, supporting structurally higher gross margins and likely driving earnings expansion.

Read the complete narrative. Read the complete narrative.

Want to see what sits behind that valuation gap? The narrative leans heavily on modest revenue growth, fatter margins, and a future earnings multiple that assumes consistent execution without requiring extreme forecasts.

Result: Fair Value of $90.21 (UNDERVALUED)

However, this upside case still leans on assumptions that could be challenged if competitive pricing keeps pressuring distribution margins or if international regulatory setbacks weigh on growth.

Next Steps

The mix of cautious sentiment and potential upside in this article points to a stock that investors are still debating, so act quickly, review the underlying numbers for yourself and then weigh up the 2 key rewards and 2 important warning signs

Looking for more investment ideas?

If Henry Schein is on your radar, do not stop there. Use a few focused stock lists to pressure test your thinking and uncover fresh opportunities.

• Spot potential value opportunities early by scanning 50 high quality undervalued stocks that combine reasonable pricing with stronger fundamentals than the market might be giving credit for right now.
• Prioritize resilience by reviewing 66 resilient stocks with low risk scores where companies show steadier risk scores that may suit a portfolio focused on smoother returns.
• Hunt for tomorrow’s potential standouts by checking the screener containing 22 high quality undiscovered gems before these stocks appear on everyone else’s radar.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.